Antimicrobial formulary and restrictions

Search and find antimicrobial medicines and prescribing restrictions for paediatric patients.

In For health professionals

AMS formulary and prescribing categories

Our formulary lists antimicrobial medicines and their prescribing indications. Prescribing indications are based on Queensland Health’s List of approved medicines (LAM) and our paediatric guidelines for infection management.

We categorise antimicrobial medicines as unrestricted, restricted, or reserved for use. There’s a different approval process to access medicines based on the category. Before you prescribe an antimicrobial medicine check the formulary for its restriction category.

Read our Antimicrobial: prescribing, management and stewardship procedure [PDF 1069.13 KB] to learn more. You can also see the approval process flowchart [PDF 1069.13 KB] on page 5.

Unrestricted (green) antimicrobials

Antimicrobials you can prescribe for a clinically appropriate indication and length of time. You don’t need approval to prescribe unrestricted antimicrobials for standard indications and durations of treatment.

Restricted (amber) antimicrobials

Antimicrobials you can only prescribe for listed indications for a specific time frame. You need approval to prescribe restricted antimicrobials outside of the indications or time frames.

Reserved (red) antimicrobials

Antimicrobials you need approval to prescribe.

Approval and documentation process

If you’re prescribing a reserved or restricted antimicrobial outside of its pre-authorised indication you need:

approval from the paediatric infection specialist or the infectious diseases (ID) fellow on duty
to document the unique AMS approval code provided by the paediatric infection specialist or fellow.

You need to document all antimicrobial prescriptions in ieMR and Metavision and include the indication, dose, duration of the treatment and intended review date. Read page 6 of our procedure [PDF 1069.13 KB] for more information.

If the antimicrobial you’re prescribing isn't on Queensland Health's List of approved medicines (LAM) you'll also need individual patient approval (IPA). Queensland Health staff can use our online individual patient approval portal (CGOV) on the intranet to request approval.

Some restricted or reserved antimicrobials might also need Special Access Scheme (SAS) approval. You can apply on the Therapeutic Goods Administration website.

Prescribers need to document all approvals in ieMR and Metavision before we can dispense any restricted or reserved medicines. Read page 6 of our procedure [PDF 1069.13 KB] for more information.

Search the antimicrobial formulary

Antimicrobial medicines are listed based on generic name. Individual patient approval with the AMS approval code provided by ID team is required for non LAM use or use outside of pre approved indications.

Antimicrobial name	Approval requirements	Restriction category
Amoxicillin (oral/IV)	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Amoxicillin/clavulanic acid (oral)	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Amphotericin B lozenges (oral)	Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Ampicillin IV	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Benzathine penicillin (IM)	Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Benzylpenicillin (IV)	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Cefaclor (oral)	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Cefalexin (oral)	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Cefazolin (IV) – inpatient	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Cefiderocol (IV)	ID consult and approval required	Reserved (red)
Chloramphenicol eyedrops (topical)	Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Clotrimazole (topical)	Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Dicloxacillin (IV/oral)	Product discontinued January 2022 Approval required for all indications	Reserved (red)
Flucloxacillin (IV/oral)	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Framycetin, gramicidin and dexamethasone – Sofradex or Otodex (eardrops)	Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Metronidazole (oral/IV)	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Miconazole (topical)	Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Nitrofurantoin (oral capsules)	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Nystatin (oral or topical)	Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Permethrin (topical)	Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Phenoxymethylpenicillin (oral)	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Pyrantel (oral)	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Roxithromycin (150mg oral tablets)	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Tinidazole (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) on the health.gov.au website approval required	Reserved (red)
Trimethoprim (oral tablets)	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Trimethoprim/sulfamethoxazole (oral)	Pre-approved for first dose challenge, IDT or SPT and desensitisation by paediatric immunologist or allergist Clinically appropriate indications and duration as per Australian Therapeutic Guidelines or CHQ Infection/AMS guidelines	Unrestricted (green)
Aciclovir (eye ointment)	Pre-approved indications: Upon advice of ophthalmologist	Restricted (amber)
Aciclovir (topical cream)	Pre-approved indications: Upon advice of haematologist or oncologist	Restricted (amber)
Aciclovir (IV/oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): IV Aciclovir not suitable for IDT or SPT due to alkaline pH Herpes simplex encephalitis [PDF 555.79 KB] (IV only - 72 hours) Cutaneous or mucosal herpes simplex in immunosuppressed patients (72 hours) Disseminated herpes zoster in immunocompromised patients (72 hours) Varicella zoster encephalitis or pneumonia in all patients (IV only - 72 hours) Ophthalmic herpes zoster (72 hours) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required.	Restricted (amber)
Albendazole (oral)	Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT by paediatric immunologist or allergist For prophylaxis against Snail and Slug Ingestion (Angiostrongylus cantonensis infection/ rat lung worm) [PDF 170.28 KB] As per QH LAM criteria.	Restricted (amber)
Amoxicillin/clavulanate (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Pre-approved for first dose challenge, IDT or SPT by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required Retropharyngeal abscess (24 hours) [PDF 555.79 KB] Animal bites – see guideline (24 hours) [PDF 555.79 KB] Facial cellulitis of dental origin (24 hours) [PDF 1522.35 KB] Uncomplicated appendicitis (72 hours) [PDF 555.79 KB] Complicated appendicitis, peritonitis, NEC (96 hours) [PDF 555.79 KB]	Restricted (amber)
Amoxicillin, clarithromycin and esomeprazole (triple therapy)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Eradication of proven Helicobacter pylori for 7 to 14 days under care of a Gastroenterologist according to the Australian Therapeutic Guidelines (Antibiotics).	Restricted (amber)
Amphotericin (Liposomal) IV (Ambisome)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Pre-approved for first dose challenge, IDT or SPT by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required Prolonged febrile neutropenia (24 hours then ID review required) [PDF 622.23 KB] Antifungal prophylaxis in oncology inpatients – see guideline (72 hours then ID review required) [PDF 632.94 KB] Liver transplant surgical prophylaxis – see guideline (5 days) [PDF 420.24 KB]	Restricted (amber)
Azithromycin (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Pre-approved for first dose challenge, IDT or SPT by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required Severe community acquired pneumonia (PICU) (24 hours then ID review required) [PDF 555.79 KB] Severe acute B.pertussis infection (PICU) (24 hours then ID review required) [PDF 563.28 KB]	Restricted (amber)
Azithromycin (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Azithromycin tablets: For 48 hours in children >1 year of age with community acquired pneumonia managed as inpatient (for discharge/outpatients/HITH - ID approval required) Azithromycin suspension shortage (April/May 2024) - refer to Medication communique for information [PDF 796.8 KB] Patients with cystic fibrosis – see criteria in guideline [PDF 613.07 KB] Patients with non CF bronchiectasis – see criteria in guideline [PDF 458.54 KB] Severe community acquired pneumonia (PICU) (24 hours then ID review required) [PDF 555.79 KB] Severe acute B.pertussis infection (PICU) (24 hours then ID review required) [PDF 563.28 KB] Sexually transmitted disease (STD) prophylaxis – see guideline (single dose) for Queensland Health staff on the intranet Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Cefazolin – with preservative (eyedrops)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Upon advice from ophthalmology for Acute management of open globe injuries, keratitis, endophthalmitis [PDF 317.58 KB]	Restricted (amber)
Cefazolin (IV) (HITH)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): According to HITH ED pathway [PDF 443.46 KB] first dose in ED, then up to 48 hours on HITH, then ID review and AMS code required for the following indications: community acquired pneumonia (not tolerating oral therapy), cellulitis, lymphadenitis and pre-septal or peri-orbital cellulitis	Restricted (amber)
Cefepime (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Upon advice from Renal consultant according to CHQ Paediatric Peritoneal Dialysis Peritonitis Clinical Pathway [PDF 408.07 KB] (72 hours then ID review required) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Cefotaxime (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Patient with non CF bronchiectasis as per guideline (up to 14 days) [PDF 458.54 KB] Meningitis (48 hours) [PDF 555.79 KB] Community acquired sepsis (72 hours) [PDF 555.79 KB] CSF shunt infection (48 hours) [PDF 555.79 KB] Severe or life threatening community acquired pneumonia (Up to 48 hours) [PDF 555.79 KB] Tracheitis or epiglottitis (24 hours) [PDF 555.79 KB] Mastoiditis (72 hours) [PDF 555.79 KB] Cholangitis (72 hours) [PDF 555.79 KB] Orbital cellulitis (48 hours) [PDF 555.79 KB] HiB unvaccinated – Septic arthritis, osteomyelitis, moderate to severe periorbital (48 hours) [PDF 555.79 KB] Suspected necrotising fasciitis (24 hours) [PDF 555.79 KB] Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Cefoxitin (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use in accordance with CHQ paediatric surgical antibiotic prophylaxis protocol [PDF 420.24 KB] for abdominal and biliary surgery (see guideline for duration) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Ceftazidime (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Febrile neutropenia (oncology) – see criteria in guideline (72 hours) for Queensland Health staff on the intranet Patients with cystic fibrosis – see criteria in guideline (Up to 14 days) [PDF 613.07 KB] Patient with non CF bronchiectasis – see criteria in guideline (Up to 14 days) [PDF 458.54 KB] Nosocomial sepsis – delayed type hypersensitivity (PICU) (72 hours) [PDF 563.28 KB] Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Ceftazidime (intravitreal injection)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Upon advice from ophthalmology for Acute management of open globe injuries (1 dose) [PDF 317.58 KB]	Restricted (amber)
Ceftriaxone (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Patient with non CF bronchiectasis as per guideline (Up to 14 days) [PDF 458.54 KB] Febrile non-neutropenia (72 hours) [PDF 555.79 KB] Meningitis (48 hours) [PDF 555.79 KB] Community acquired sepsis (72 hours) [PDF 555.79 KB] CSF shunt infection (48 hours) [PDF 555.79 KB] Severe or life threatening community acquired pneumonia (up to 48 hours) [PDF 555.79 KB] Tracheitis/epiglottitis (24 hours) [PDF 555.79 KB] Mastoiditis (72 hours) [PDF 555.79 KB] Cholangitis (72 hours) [PDF 555.79 KB] Orbital cellulitis (48 hours) [PDF 555.79 KB] HiB unvaccinated – Septic arthritis, osteomyelitis, moderate to severe periorbital (48 hours) [PDF 555.79 KB] Suspected necrotising fasciitis (24 hours) [PDF 555.79 KB] Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Ceftriaxone (IV) (HITH)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): HITH – Patients with non CF bronchiectasis as per guideline (up to 14 days, first dose as inpatient) [PDF 458.54 KB] According to HITH ED pathway [PDF 443.46 KB] first dose in ED, then up to 48 hours on HITH – ID review and AMS code required for ongoing treatment for the following indications: community acquired pneumonia (not tolerating oral therapy), cellulitis, lymphadenitis, pre-septal or peri-orbital cellulitis	Restricted (amber)
Cefuroxime (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Chloramphenicol eye ointment	Pre-approved indications: For ophthalmic use only	Restricted (amber)
Cefazolin intravitreal and intracameral injection	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Upon advice from ophthalmology for Acute management of open globe injuries (1 dose) [PDF 317.58 KB]	Restricted (amber)
Ciprofloxacin (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Patients with cystic fibrosis – see criteria in guideline [PDF 613.07 KB] Patient with non-CF bronchiectasis – see criteria in guideline [PDF 458.54 KB] Single dose as chemoprophylaxis of meningococcal contacts on advice from Infectious diseases consultant/public health medical officer (according to CHQ antibiocard [PDF 555.79 KB]) According to Acute management of open globe injuries [PDF 317.58 KB] guideline (5 days) Chemoprophylaxis of meningococcal contacts [PDF 555.79 KB] on advice from ID consultant (single dose) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Ciprofloxacin eardrops	Pre-approved indications: As per QH LAM criteria and CHQ otitis externa guideline [PDF 287.53 KB]	Restricted (amber)
Ciprofloxacin/hydrocortisone – Ciproxin HC (eardrops)	Pre-approved indications: As per QH LAM criteria for Deadly Ears ENT outreach service QCH use as per CHQ Patient group medication approval list indications for Queensland Health staff on the intranet	Restricted (amber)
Clindamycin (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): In neonates only, for approved indications – sepsis with nmMRSA risk factors [PDF 555.79 KB] (48 hours) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Clindamycin (intravitreal/intracameral injection)	ID consult and approval required	Reserved (red)
Clindamycin (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Mild cellulitis [PDF 555.79 KB] – nmMRSA risk factors (72 hours) Mild periorbital cellulitis [PDF 555.79 KB] – nmMRSA risk factors (72 hours) Impetigo [PDF 555.79 KB] – nmMRSA risk factors (72 hours) Cervical lymphadenitis [PDF 555.79 KB] – nmMRSA risk factors (72 hours) Cystic fibrosis [PDF 613.07 KB] – outpatient MRSA eradication (14 days) Pre-approved for first dose challenge bypaediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Colistin (inhaled)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Cystic fibrosis – according to eligibility criteria in guideline [PDF 613.07 KB]	Restricted (amber)
Dapsone (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Second line agent for PJP prophylaxis in oncology/haematology patients Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Doxycycline (IV – SAS)	Pre-approved indications: For single dose: use by physicians trained in interventional radiology and with proper skills in sclerotherapy for use in sclerotherapy for treatment of lymphatic malformations in paediatric patients (SAS approval required)	Restricted (amber)
Doxycycline (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For 48 hours in children >8 years of age with community acquired pneumonia managed as inpatient (for discharge/outpatients/HITH - ID approval required) Acne – adolescents (up to 3 months under guidance of dermatologist) Water immersed wound infection [PDF 181.31 KB] according to guideline criteria (Children over 8 years of age) (24 hours) Dental avulsion – in children over 8 years of age (7 days) [PDF 1522.35 KB]	Restricted (amber)
Erythromycin (IV/oral)	Pre-approved: Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Famciclovir (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Herpes zoster in immunocompetent patients (72 hours) Herpes zoster in immunocompromised patients (72 hours) Ophthalmic herpes zoster (72 hours) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Fluconazole (IV/ oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use in accordance with Oncology and haematology antifungal prophylaxis and treatment guideline [PDF 632.94 KB] Pre-approved for first dose challenge, SPT or IDT by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Gentamicin (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Neonatal sepsis (meningitis excluded) [PDF 555.79 KB] (48 hours) Neonatal community acquired pneumonia [PDF 555.79 KB] (48 hours) Community acquired sepsis (meningitis excluded) [PDF 555.79 KB] (48 hours) Urosepsis/ UTI/ Pyelonephritis [PDF 555.79 KB] (up to 48 hours) Febrile neutropenia – septic shock [PDF 555.79 KB] (24 hours) As per Surgical antibiotic prophylaxis guideline [PDF 420.24 KB] (single dose) Endocarditis [PDF 555.79 KB] (24 hours) Complicated appendicitis [PDF 555.79 KB] (up to 72 hours) Hospital In The Home (HITH) Emergency/ED pathways- [PDF 443.46 KB] Urinary tract infection/ Pyelonephritis (1st dose in ED, up to 48 hours on HITH, then ID approval required) Pre-approved for first dose challenge, SPT or IDT by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Gentamicin eye drops	Pre-approved indications: Use upon advice from ophthalmology team	Restricted (amber)
Griseofulvin (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use in recalcitrant laboratory proven tinea infection according to the Australian Therapeutic Guidelines (Antibiotic) Pre-approved for first dose challenge bypaediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Hydroxychloroquine (oral)	Pre-approved indications: For use according to the QH LAM by an authorised prescriber in accordance with the Medicines and Poisons (Medicines) Regulation 2021	Restricted (amber)
Itraconazole (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Cystic fibrosis – Allergic bronchopulmonary aspergillosis (ABPA) [PDF 613.07 KB]) (up to 3 months) For use in accordance with oncology and haematology antifungal prophylaxis and treatment guideline [PDF 632.94 KB] Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Lincomycin (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Community acquired sepsis [PDF 555.79 KB], meningitis excluded, nmMRSA risk factors (48 hours) Empyema [PDF 555.79 KB] (48 hours) Severe or life-threatening MRSA or pneumonia (PICU) [PDF 563.28 KB] (24 hours) Immediate severe beta-lactam hypersensitivity according to indications listed in the CHQ Antibiocard [PDF 555.79 KB] (24 hours) Severe cervical lymphadenitis with nmMRSA risk factors [PDF 555.79 KB] (48 hours) Osteomyelitis with nmMRSA risk factors [PDF 555.79 KB] (48 hours) Septic arthritis with nmMRSA risk factors [PDF 555.79 KB] (48 hours) Moderate to severe periorbital cellulitis with nmMRSA risk factors [PDF 555.79 KB] (48 hours) Severe cellulitis with nmMRSA risk factors [PDF 555.79 KB] (48 hours) Suspected necrotising fasciitis [PDF 555.79 KB] (24 hours) For use in accordance with CHQ surgical antibiotic prophylaxis guidelines [PDF 420.24 KB], in patients who have an immediate severe type hypersensitivity to penicillins/cephalosporins (single dose, ongoing use ID approval required) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Mebendazole (oral)	Pre-approved indications: According to QH LAM indications and Australian Therapeutic Guidelines (Antibiotics) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Minocycline (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Acne (adolescents) upon advice from Dermatologist (up to 3 months) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Mupirocin (intranasal)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use in according to CHQ management of boils (furunculosis) (MSSA and MRSA decolonisation) [PDF 361.1 KB] or for eradication of staph aureus nasal colonisation in cardiac surgery patients [PDF 420.24 KB]	Restricted (amber)
Mupirocin (topical)	Pre-approved indications: Prevention of peritoneal dialysis catheter exit site infection for Queensland Health staff on the intranet	Restricted (amber)
Neomycin (oral)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval requireded	Reserved (red)
Ofloxacin (eyedrops)	Pre-approved indications: Use upon advice from ophthalmology team	Restricted (amber)
Oseltamivir (oral)	Pre-approved indications: For use according to Queensland Infection Clinical Network Guidelines for prescribing oseltamivir for seasonal influenza in 2022 on the Queensland Health website	Restricted (amber)
Piperacillin/tazobactam (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Febrile neutropenia [PDF 622.23 KB] (72 hours) Cystic fibrosis – see guideline [PDF 613.07 KB] (up to 14 days – inpatient/HITH) Non CF bronchiectasis – as per guideline eligibility criteria [PDF 458.54 KB] (Up to 14 days – inpatient only, HITH – ID approval required) Complicated appendicitis [PDF 555.79 KB] (up to 7 days) Peritonitis [PDF 555.79 KB] (72 hours) Necrotising enterocolitis [PDF 555.79 KB] (72 hours) Compound fractures [PDF 555.79 KB] (24 hours) Surgical antibiotic prophylaxis – liver [PDF 420.24 KB] and renal [PDF 420.24 KB] transplantation (up to 24 hours) Surgical antibiotic prophylaxis – percutaneous cholangiogram [PDF 420.24 KB] and burns (contaminated wound) [PDF 420.24 KB] (1 dose) Fever in patient with CVAD in-situ according to eligibility criteria [PDF 647.24 KB] (up to 48 hours) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Posaconazole (oral)	Pre-approved indications: Antimould prophylaxis as per oncology and haematology antifungal prophylaxis and treatment guideline criteria [PDF 632.94 KB]– Treatment – ID approval required Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Rifampicin (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Chemoprophylaxis of meningococcal contacts [PDF 555.79 KB] on advice from ID consultant (48 hours) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Teicoplanin (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Single dose according to eligibility criteria in CHQ-proc-03455 Management of compromised Central Venous Access Device (CVAD) [PDF 304.16 KB] Post cardiac surgery (within 72 hours of surgery) suspicion of infection without a focus [PDF 563.28 KB] (24 hours) Deep cardiac surgical wound infection (mediastinitis suspected) [PDF 563.28 KB] (24 hours) Cardiac patient with CVAD associated or bloodstream infection focus [PDF 563.28 KB] (24 hours) Nosocomial sepsis (hospital-acquired and healthcare associated sepsis) [PDF 563.28 KB] (48 hours) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Terbinafine (topical)	Pre-approved indications: For use according to QH LAM criteria	Restricted (amber)
Terbinafine (oral)	Pre-approved indications: Upon advice from dermatologist for microbiologically proven chronic onychomycosis or extensive tinea unresponsive to griseofulvin or in patients intolerant of griseofulvin according to Australian Therapeutic Guidelines (Antibiotic) and QH LAM criteria Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Tobramycin (IV/inhaled/nebulised)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Cystic fibrosis – as per guideline criteria [PDF 613.07 KB](IV therapy – up to 14 days, inhaled/nebulised – see guideline) Non CF bronchiectasis [PDF 458.54 KB] (IV – inpatient up to 14 days, HITH - ID approval required) Non CF bronchiectasis [PDF 458.54 KB] (inhaled/nebulised – QCH use endorsed as per guideline) Other sites – as per local ID approval practices	Restricted (amber)
Tobramycin (eyedrops/eye ointment)	Pre-approved indications: Upon ophthalmologist advice	Restricted (amber)
Trimethoprim/sulfamethoxazole (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Initial treatment of PJP pneumonia where oral therapy is not tolerated (Up to 48 hours, ID consult and approval for ongoing use required) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Valaciclovir (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Prophylaxis of viral infection for 12 months following allogeneic bone marrow transplant Prophylaxis of viral infection for 3 months following autologous bone marrow transplant Cutaneous or mucosal herpes simplex in immunosuppressed patients (72 hours) Herpes zoster in immunocompromised patients (72 hours) Ophthalmic herpes zoster (72 hours) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
ValGANciclovir (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use as CMV prophylaxis only in accordance with the CHQ liver transplant protocol and CHQ renal transplant protocol for Queensland Health staff on the intranet ID consult and approval required for prophylaxis in other transplant cohorts and for CMV treatment	Restricted (amber)
Vancomycin (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Penetrating eye injuries or open globe injuries as per guideline [PDF 530.08 KB] (48 hours) Febrile neutropenia [PDF 622.23 KB] – AML, CVAD associated fever, septic shock (48 hours) Single dose according to eligibility criteria in CHQ-proc-03455 Management of compromised Central Venous Access Device (CVAD) [PDF 304.16 KB] Peri-operative MRSA cover per Surgical antibiotic prophylaxis guideline [PDF 420.24 KB] (1 dose) Meningitis (24 hours) [PDF 555.79 KB] Community acquired sepsis (48 hours) [PDF 555.79 KB] CSF shunt infection (48 hours) [PDF 555.79 KB] Severe or life threatening community acquired pneumonia (up to 48 hours) [PDF 555.79 KB] Endocarditis [PDF 555.79 KB] (24 hours) Pre-approved for first dose challenge by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Restricted (amber)
Vancomycin (intravitreal/intracameral injection)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Upon advice from ophthalmology for Acute management of Open Globe Injuries (1 dose) [PDF 317.58 KB]	Restricted (amber)
Voriconazole (intravitreal/ intracameral injection)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Upon advice from ophthalmology for Acute management of open globe injuries (1 dose) [PDF 317.58 KB]	Restricted (amber)
Abacavir (oral)	ID consult and approval required	Reserved (red)
Adefovir (oral)	ID consult and approval required	Reserved (red)
Amikacin (IV/nebulised)	ID consult and approval required	Reserved (red)
Amorolfine (topical solution)	ID consult and approval required	Reserved (red)
Amphotericin B Lipid complex IV (SAS-Abelcet)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS)  – Custom Portal on the health.gov.au website approval required	Reserved (red)
Amphotericin IV (SAS-Fungizone)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS)  – Custom Portal on the health.gov.au website approval required	Reserved (red)
Anidulafungin (IV)	ID consult and approval required	Reserved (red)
Artemeter/lumefantrine (Riamet) (oral)	ID consult and approval required	Reserved (red)
Artesunate (SAS) (IV)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS)  – Custom Portal on the health.gov.au website approval required	Reserved (red)
Atazanavir (oral)	ID consult and approval required	Reserved (red)
Atovaquone (oral)	ID consult and approval required	Reserved (red)
Atovaquone/proguanil (oral)	ID consult and approval required	Reserved (red)
Aztreonam (IV/nebulised) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS)  – Custom Portal on the health.gov.au website approval required	Reserved (red)
Bacitracin (topical) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS)  – Custom Portal on the health.gov.au website approval required	Reserved (red)
Bedaquiline (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS)  – Custom Portal on the health.gov.au website approval required	Reserved (red)
Benznidazole (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS)  – Custom Portal on the health.gov.au website approval required	Reserved (red)
Brincidofovir – compassionate access	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required CHQMAC approval required	Reserved (red)
Capreomycin (IV) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Tixagevimab/cilgavimab (Evusheld)	ID consult and approval required	Reserved (red)
Caspofungin (IV)	ID consult and approval required	Reserved (red)
Cefpodoxime (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Ceftolozane/tazobactam (IV)	ID consult and approval required	Reserved (red)
Ceftazidime/avibactam (IV)	ID consult and approval required	Reserved (red)
Ceftaroline (IV)	ID consult and approval required	Reserved (red)
Chloramphenicol (IV) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Chloroquine (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Cidofovir (IV)	ID consult and approval required	Reserved (red)
Ciprofloxacin (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Water immersed wound infection [PDF 181.31 KB] – prophylaxis for deep tissue injury including bones, joint or tendons or empiric IV treatment of established infection (up to 24 hours) Penetrating eye injuries or open globe injuries as per guideline [PDF 317.58 KB] (48 hours) Alternative for immediate severe type hypersensitivity as outlined in CHQ Antibiocard [PDF 555.79 KB] (24 hours)	Restricted (amber)
Clofazimine (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Colistin (IV)	ID consult and approval required	Reserved (red)
Clarithromycin (oral)	ID consult and approval required	Reserved (red)
Cycloserine (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Daclatasvir (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Daptomycin (IV)	ID consult and approval required	Reserved (red)
Darunavir (oral)	ID consult and approval required	Reserved (red)
Delamanid (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Dolutegravir (oral)	Approval required: ID consult and approval required Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Compassionate use – CHQMAC approval required	Reserved (red)
Doripenem (IV) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Efavirenz (oral)	ID consult and approval required	Reserved (red)
Elvitegravir (oral) – as part of FDC product	ID consult and approval required	Reserved (red)
Emtricitabine (oral) – as part of FDC product	ID consult and approval required	Reserved (red)
Enfuviritide (oral)	ID consult and approval required	Reserved (red)
Entecavir (oral)	ID consult and approval required	Reserved (red)
Ethambutol (oral) (IV – SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Ertapenem (IV)	ID consult and approval required	Reserved (red)
Erythromycin (IV)	ID consult and approval required	Reserved (red)
Ethionamide (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Fidaxomicin (oral)	ID consult and approval required	Reserved (red)
Flucytosine (IV/oral)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Fosfomycin (oral/IV)	Oral: ID consult and approval required IV formulation: Approval required Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Foscarnet (IV)	ID consult and approval required	Reserved (red)
Fusidic acid (sodium fusidate) (oral)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Ganciclovir (IV)	ID consult and approval required	Reserved (red)
Imipenem/cilastatin (IV)	ID consult and approval required	Reserved (red)
Isavuconazole (IV/oral)	ID consult and approval required	Reserved (red)
Isoniazid (oral/IV) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use IV formulation: Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Ivermectin (oral)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use IV formulation: Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Ketoconazole (oral/shampoo)	ID consult and approval required	Reserved (red)
Lamivudine (oral)	ID consult and approval required	Reserved (red)
Letermovir (IV/oral)	ID consult and approval required	Reserved (red)
Levofloxacin (IV/oral)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Linezolid (IV/oral)	ID consult and approval required	Reserved (red)
Lopinavir/ritonavir (oral)	ID consult and approval required	Reserved (red)
Nirmatrelvir/ritonavir (Paxlovid) (oral)	ID consult and approval required	Reserved (red)
Molnupiravir (oral)	ID consult and approval required	Reserved (red)
Maraviroc (oral)	ID consult and approval required	Reserved (red)
Maribavir (oral)	ID consult and approval required	Reserved (red)
Mefloquine (oral)	ID consult and approval required	Reserved (red)
Miltefosine (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Moxifloxacin (IV/oral)	ID consult and approval required	Reserved (red)
Meropenem/vaborbactam (IV) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Meropenem (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Febrile neutropenia [PDF 622.23 KB] and as peri-operative prophylaxis for liver transplantation [PDF 420.24 KB] or renal transplantation [PDF 420.24 KB]– patients with immediate severe hypersensitivity to penicillins/cephalosporins (Up to 24 hours) External wound or inoculation with suspected necrotising fasciitis [PDF 555.79 KB] (Up to 24 hours)	Reserved (red)
Methenamine hippurate (oral)	ID consult and approval required	Reserved (red)
Micafungin (IV)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use in accordance with oncology and haematology antifungal prophylaxis and treatment guideline [PDF 632.94 KB]. Pre-approved for first dose challenge, SPT or IDT by paediatric immunologist or allergist Ongoing use/desensitisation – ID approval required	Reserved (red)
Nalidixic acid (PO) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Natamycin eyedrops (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Netilmicin (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Nevirapine (oral)	ID consult and approval required	Reserved (red)
Niclosamide (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Nirsevimab	ID consult and IPA required for patients who do not meet the QLD RSV prevention program eligibility criteria.	Reserved (red)
Nitazoxanide (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Reserved (red)
Norfloxacin (oral)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Palivizumab (IM)	ID consult and approval required	Reserved (red)
Paromomycin (oral/topical) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Para-aminosalicylic acid (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Pentamidine (IV/nebulised)	ID consult and approval required	Reserved (red)
Peramivir (IV)	ID consult and approval required	Reserved (red)
Pivmecillinam (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Polymyxin B (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Posaconazole (IV)	ID consult and approval required	Reserved (red)
Praziquantel (oral)	ID consult and approval required	Reserved (red)
Pretomanid (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Primaquine (oral)	ID consult and approval required	Reserved (red)
Pristinamycin (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Pylera – bismuth, metronidazole, tetracycline (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Pyrazinamide (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Pyrimethamine (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Quinine (IV/ oral)	ID consult and approval required	Reserved (red)
Quinupristin/dalfopristin (IV) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Raltegravir (oral)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use 100 mg tablets Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Remdesivir (IV)	ID consult and approval required	Reserved (red)
Ribavirin (oral)	ID consult and approval required	Reserved (red)
Ribavirin (IV)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required Additional national medical stockpile approval from the CMO may be required	Reserved (red)
Rifabutin (oral)	ID consult and approval required	Reserved (red)
Rifampicin (IV)	ID consult and approval required	Reserved (red)
Rifapentine (oral) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Rifaximin (oral)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Suspension: Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Rilpirivine – with tenofovir and emtricitabine (oral)	ID consult and approval required	Reserved (red)
Sarilumab (IV)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Sofosbuvir (oral)	ID consult and approval required	Reserved (red)
Streptomycin (IM) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Sulfadiazine (oral)	ID consult and approval required	Reserved (red)
Tafenoquine (oral)	ID consult and approval required	Reserved (red)
Taurolidine/citrate antiseptic lock (Taurolock)	ID consult and approval required	Reserved (red)
Tedizolid (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Telithromycin (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Tenofovir (oral)	ID consult and approval required	Reserved (red)
Tetracycline (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Triclosan skin wash	ID consult and approval required	Reserved (red)
Tigecycline (IV)	ID consult and approval required	Reserved (red)
Vancomycin (oral)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Suspension: Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Voriconazole (IV/eyedrops)	ID consult and approval required	Reserved (red)
Zanamavir (inhaled)	ID consult and approval required	Reserved (red)
Zidovudine (oral/IV) (SAS)	Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use IV formulation: Special Access Scheme (SAS) – Custom Portal on the health.gov.au website approval required	Reserved (red)
Glecaprevir/pibrentasvir (Maviret) (oral)	ID consult and approval required	Reserved (red)
Sofosbuvir/velpatasvir (Epclusa) (oral)	ID consult and approval required	Reserved (red)
Ledipasvir/sofosbuvir (Harvoni) (oral)	ID consult and approval required	Reserved (red)
Voriconazole (oral)	Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use in accordance with oncology/haematology antifungal prophylaxis and treatment guideline [PDF 632.94 KB]. Pre-approved for first dose challenge, SPT or IDT by Paediatric immunologist/allergist. Ongoing use/desensitisation – ID approval required.	Restricted (amber)

Last updated: April 2024